Home >   Products   >  Advanced Search

Rufinamide
(CAS RN:106308-44-5 Product Number:R0143)

Structure

Rufinamide
Synonym 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

General Information

Product Number R0143

* Items available from stock in Japan will be delivered in 10 business days.
* Please contact us if you need further information.
(Sales Dept Tel: +32 (0)3 735 07 00 E-mail: Sales-EU@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that for some of our products we cannot offer bulk quantities.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(HPLC)
Storage Temperature
M.F. / M.W. C10H8F2N4O=238.20
CAS RN 106308-44-5
Related CAS RN
MDL Number MFCD00865314
Packaging and Container
  • Product Details
  • Safety & Regulations

Specification

Purity(HPLC) min. 98.0 area%
Elemental analysis(Nitrogen) 22.50 to 24.50 %
Melting point 239.0 to 243.0 deg-C

References

Reaxys-RN 13495800
PubChem SID 253662493
Merck Index(14) 8293

GHS

Pictogram
Signal Word Warning
Hazard Statements
  • H336
  • :May cause drowsiness or dizziness.
Precautionary Statements
  • P261
  • :Avoid breathing dust/fume/gas/mist/vapours/spray.
  • P271
  • :Use only outdoors or in a well-ventilated area.
  • P304+P340+P312
  • :IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER or doctor if you feel unwell.
  • P403+P233
  • :Store in a well-ventilated place. Keep container tightly closed.
  • P405
  • :Store locked up.
  • P501
  • :Dispose of contents/container through a waste management company authorized by the local government.

Transport Information

HS Number 2933998090

Application

Rufinamide: A Broad-Spectrum Anticonvulsant Agent

Rufinamide is an antiepileptic agent with a triazole derivative structure. It is showed broad-spectrum anticonvulsant properties at nontoxic doses in animal models. The principal mechanism of action of rufinamide is considered to be the modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Rufinamide is extensively metabolized in the liver by non-CYP450 enzymes. Recently, rufinamide is in development for the adjunctive treatment of refractory epilepsy, Lennox-Gastaut syndrome (LGS). (The product is for research purpose only.)

References

PubMed Literature

Page Top